The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical trials based on cell engineering and adoptive cell therapies.
Its aims are as follows:
AIM1 : To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2 : GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks (plasmid DNA, cell banks).
AIM3 : Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability); Gene transfer/expression.
AIM4 : To monitor patients? samples post-infusion (e.g., FACS, Q-PCR).
AIM5 : To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).
|Karimov, Rashad R; Tan, Derek S; Gin, David Y (2018) Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement-intramolecular ketene hetero-Diels-Alder reaction. Tetrahedron 74:3370-3383|
|Fass, Josh; Sivak, David A; Crooks, Gavin E et al. (2018) Quantifying Configuration-Sampling Error in Langevin Simulations of Complex Molecular Systems. Entropy (Basel) 20:|
|Mauguen, Audrey; Seshan, Venkatraman E; Ostrovnaya, Irina et al. (2018) Estimating the probability of clonal relatedness of pairs of tumors in cancer patients. Biometrics 74:321-330|
|Tanner, Edward J; Filippova, Olga T; Gardner, Ginger J et al. (2018) A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol 151:433-437|
|Arbour, Kathryn C; Kris, Mark G; Riely, Gregory J et al. (2018) Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 124:105-109|
|Soslow, Robert A; Murali, Rajmohan (2018) A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract. Semin Diagn Pathol 35:95-107|
|Kao, Yu-Chien; Owosho, Adepitan A; Sung, Yun-Shao et al. (2018) BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42:604-615|
|Knight, Julia A; Blackmore, Kristina M; Fan, Jing et al. (2018) The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Res 20:23|
|Nashat, Melissa A; Ricart Arbona, Rodolfo J; Riedel, Elyn R et al. (2018) Comparison of Diagnostic Methods and Sampling Sites for the Detection of Demodex musculi. J Am Assoc Lab Anim Sci 57:173-185|
|Roth, Allen J; Shuman, Stewart; Schwer, Beate (2018) Defining essential elements and genetic interactions of the yeast Lsm2-8 ring and demonstration that essentiality of Lsm2-8 is bypassed via overexpression of U6 snRNA or the U6 snRNP subunit Prp24. RNA 24:853-864|
Showing the most recent 10 out of 8799 publications